Radiotherapy Market Overview, Cost Structure Analysis, Growth Opportunities and Forecast to 2025
Radiotherapy Market Research Report 2018 examines the market dynamics, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual and potential market situation, and future outlook. The Radiotherapy Market research includes historic data from 2017 to 2024 and forecasts until 2024.
Global Radiotherapy Market is expected to reach USD 9.3 billion by 2024 from USD 5.2 billion in 2016, at a CAGR of 7.5% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Click Here for Free Sample Report @ databridgemarketresearch.com/request-a-sample/?dbmr=globa...
According to the study conducted by the Texas oncology, a study was conducted on 715 women who were suffering from stage 1uterine cancer. The difference the treatment with surgery alone and treatment with surgery followed by adjuvant external beam radiation therapy was studied.
It was found that the cancer recurrence rate was 4.0% and the survival rate was 81.0% in the patient treated with surgery followed by adjuvant external beam radiation therapy and the cancer recurrence rate was 14.0% and the survival rate was 85.0% in the patient who were treated with surgery alone. The survival rate was higher in treatment by surgery alone because the radiation has various side effects in women.
In Florida a study was conducted on 396 women who were suffering from stage 1 uterine cancer treated with hysterectomy, lymph node dissection and brachytherapy. From the study it was observed that the 5 years survival rate was 100.0% for cancer confined to the inner layer of cells of the uterus, 97.0% for the patients with cancer that invades less than one half of the muscle wall of the uterus and 93.0% for the patients with cancer that invades more than one half of the muscle wall of the uterus .
Increasing number of cancer treatment facilities:
According to the national cancer institute (NCI), NCI is one of the major part of nation’s cancer research effort. There are around 70 NCI designated cancer centers located in 36 states and districts of Columbia.. Approximately 250,000 patients received cancer diagnosis at NCI designated cancer center in 2017. According to the national institute of cancer prevention and research, Government of India has recognized around 27 cancer centers under the national cancer control programme in 2010 in around 21 states.
Have Any Query? Inquire here @ databridgemarketresearch.com/inquire-before-buying/?dbmr=...
Key Market Focuses on:
Elekta AB, Accuray, Inc., CIVCO Medical Solutions, Brainlab AG, C. R. Bard, Inc., IsoRay Medical, Inc., Nordion, Inc., RaySearch Laboratories AB, PRECISIS AG, Mevion Medical Systems, Inc., TechnicasRadiofiscas S.L., Hitachi, Ltd., Sumitomo Heavy Industries, Ltd., Mitsubishi Electric Corporation, ProNova Solutions, LLC, ProTom International.
Varian Medical Systems, Inc.:
1. In October 2016,Varian Medical Systems, Inc. and McKesson Specialty Health announced a strategic agreement for the distribution and servicing of Varian advanced radiotherapy equipment and software over a three period across “The US Oncology Network” and “Vantage Oncology” affiliated sites of care.
2. In October 2016,VarianMedical Systems, Inc. announced the launch of first of its kind 360 Oncology care management platform, the first software system designed to integrate and coordinate key elements of cancer so patients and their cancer teams can collaborate on achieving the best outcomes.
Elekta AB:
1. In December 2016, Elekta, Stockholm’s County Council and New KarolinskaSolna (NKS) have signed a 13-year collaboration agreement which focuses on innovation, joint research and education and training within advanced radiation therapy.
2. In March 2016, Elekta announced the strategic partnership with Genesis carewhere, the later will acquire Elekta’sLeksell Gamma Knife Icon radiosurgery systems, Versa HD linear accelerators, brachytherapy systems, software as well as services. These products and solutions will be acquired by GenesisCare cancer treatment centres in Australia, the UK and new markets.
Read more about the Global Radiotherapy Market Landscape: databridgemarketresearch.com/reports/global-radiotherapy-...
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com
Global Radiotherapy Market is expected to reach USD 9.3 billion by 2024 from USD 5.2 billion in 2016, at a CAGR of 7.5% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Click Here for Free Sample Report @ databridgemarketresearch.com/request-a-sample/?dbmr=globa...
According to the study conducted by the Texas oncology, a study was conducted on 715 women who were suffering from stage 1uterine cancer. The difference the treatment with surgery alone and treatment with surgery followed by adjuvant external beam radiation therapy was studied.
It was found that the cancer recurrence rate was 4.0% and the survival rate was 81.0% in the patient treated with surgery followed by adjuvant external beam radiation therapy and the cancer recurrence rate was 14.0% and the survival rate was 85.0% in the patient who were treated with surgery alone. The survival rate was higher in treatment by surgery alone because the radiation has various side effects in women.
In Florida a study was conducted on 396 women who were suffering from stage 1 uterine cancer treated with hysterectomy, lymph node dissection and brachytherapy. From the study it was observed that the 5 years survival rate was 100.0% for cancer confined to the inner layer of cells of the uterus, 97.0% for the patients with cancer that invades less than one half of the muscle wall of the uterus and 93.0% for the patients with cancer that invades more than one half of the muscle wall of the uterus .
Increasing number of cancer treatment facilities:
According to the national cancer institute (NCI), NCI is one of the major part of nation’s cancer research effort. There are around 70 NCI designated cancer centers located in 36 states and districts of Columbia.. Approximately 250,000 patients received cancer diagnosis at NCI designated cancer center in 2017. According to the national institute of cancer prevention and research, Government of India has recognized around 27 cancer centers under the national cancer control programme in 2010 in around 21 states.
Have Any Query? Inquire here @ databridgemarketresearch.com/inquire-before-buying/?dbmr=...
Key Market Focuses on:
Elekta AB, Accuray, Inc., CIVCO Medical Solutions, Brainlab AG, C. R. Bard, Inc., IsoRay Medical, Inc., Nordion, Inc., RaySearch Laboratories AB, PRECISIS AG, Mevion Medical Systems, Inc., TechnicasRadiofiscas S.L., Hitachi, Ltd., Sumitomo Heavy Industries, Ltd., Mitsubishi Electric Corporation, ProNova Solutions, LLC, ProTom International.
Varian Medical Systems, Inc.:
1. In October 2016,Varian Medical Systems, Inc. and McKesson Specialty Health announced a strategic agreement for the distribution and servicing of Varian advanced radiotherapy equipment and software over a three period across “The US Oncology Network” and “Vantage Oncology” affiliated sites of care.
2. In October 2016,VarianMedical Systems, Inc. announced the launch of first of its kind 360 Oncology care management platform, the first software system designed to integrate and coordinate key elements of cancer so patients and their cancer teams can collaborate on achieving the best outcomes.
Elekta AB:
1. In December 2016, Elekta, Stockholm’s County Council and New KarolinskaSolna (NKS) have signed a 13-year collaboration agreement which focuses on innovation, joint research and education and training within advanced radiation therapy.
2. In March 2016, Elekta announced the strategic partnership with Genesis carewhere, the later will acquire Elekta’sLeksell Gamma Knife Icon radiosurgery systems, Versa HD linear accelerators, brachytherapy systems, software as well as services. These products and solutions will be acquired by GenesisCare cancer treatment centres in Australia, the UK and new markets.
Read more about the Global Radiotherapy Market Landscape: databridgemarketresearch.com/reports/global-radiotherapy-...
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com